PM 360 is one of the leading magazines in the pharmaceutical marketing world, with an audience of marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, the magazine focuses on leadership as well as, “issues that directly impact critical decision making,including: planning and implementation of cutting edge strategies, trends, the latest technological advances,” in their writing.
This year, POLARISqb was honored to be one of eight companies that were named “Innovative Startups” by the magazine, along with Evozyne, Steady Shot, ImmunAI, Exocel, wePool, Conversation Health and Theraneutrics. These companies are working with some of the most advanced technologies such as artificial intelligence, nanotechnology, and synthetic biotech to address medical issues from diabetes to COVID-19, but POLARISqb stands alone as the sole quantum application selected to the list. Having developed a quantum application for designing drugs, we continue to pursue a vastly greater understanding of our chemical universe, identifying molecules that will become treatments and cures for all diseases for all people. Advancements in quantum computers technology continue to speed our work towards a quantum-based platform that provides chemical simulations at many times the speed of current traditional systems.
We are proud to be recognized for our work and innovation in drug discovery for biopharma applications by one of the leading publications on pharmaceutical marketing, a list that has in the past included companies such as H1 who went on to raise over $71M in capital funding and OM1 who raised over $86M, and Sema4 which raised over $240M. POLARISqb looks to be the next in their line of success, and the first quantum alumni of the list to revolutionize the world of biotech and pharmaceuticals.
